Latest news and press releases about Can-Fite BioPharma Ltd. (CANF): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19.
Price
| Price | $2.24 |
| Market Cap | $3M |
| Exchange | AMEX |
| Country | IL |
Valuation Ratios
| Price / Book | 0.46 |
| EV / EBITDA | 0.05 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -201.06% |
| Return on Invested Capital | -145.49% |
| Return on Assets | -103.30% |
| Gross Margin | 100.00% |
| Operating Margin | -2456.79% |
| Net Margin | -2426.67% |
Related companies: BDRX · CLDI · CMND · CNSP · GRI · JAGX · KZIA
Explore sector: Healthcare · Biotechnology
More sections of CANF: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks